Palliative Care in Pediatrics



Palliative Care in Pediatrics


Javier R. Kane

Bruce P. Himelstein



Palliative medicine for children is the art and science of family centered care aimed at enhancing quality of life and minimizing suffering. Inherent in this definition is the possibility of delivering palliative care in partnership with curative care for children with life-limiting illness or for children who may not die. Many principles already reviewed in other sections of this book are universally applicable across the age spectrum of the dying, so this chapter provides an overview of issues specific to the care of the life-threatened child.

Each year in the United States, approximately 50,000 children die, compared with approximately 2.3 million adults. National Vital Statistics for 2003, the last year published to date, demonstrate that accidents remain the number one cause of death in the age 1–19 child (1). The second leading cause of death for children for ages 1–4 is congenital malformations, deformations, and chromosomal abnormalities; ages 5–14 is malignancy; and for ages 15–19 is homicide. For infants, the leading causes of death are congenital malformations, deformations, and chromosomal abnormalities, disorders related to short gestation and low birth weight, sudden infant death syndrome, and newborns affected by maternal complications of pregnancy such as uterine rupture. Hundreds of thousands more children are living with life-threatening conditions. Goldman et al. estimated that 50/100,000 children were living with life-threatening illness (2). Feudtner et al. have done extensive research characterizing the epidemiology of childhood death (3). They have defined a group of complex chronic conditions (CCCs) “that can be reasonably expected to last at least 12 months (unless death intervenes) and to involve either several different organ systems or one organ system severely enough to require specialty pediatric care and probably some period of hospitalization in a tertiary care center.” National data demonstrated that of 1.75 million deaths occurring in the 0–24-year old population from 1979 to 1997, 5% were attributable to cancer CCCs, 16% to non–cancer CCCs, 43% to injuries, and 37% to all other death causes. Non–cancer CCCs accounted for approximately 25% of infant deaths, 20% of childhood deaths, and 7% of adolescent deaths. Death rates from CCCs are declining slowly. Feudtner estimates that each year approximately 15,000 infants, children, adolescents, young adults might benefit from supportive care services delivered both at home and in the hospital, and that on any given day, approximately 5000 are living in the last 6 months of their lives, many of whom die in hospitals after prolonged periods of inpatient care and artificial life-sustaining therapies (4, 5).

The diseases of childhood which might be appropriate for palliative care might include:



  • Conditions for which curative or life prolonging treatment is possible but may fail, such as advanced or progressive malignancy or malignancy with a poor prognosis, or complex and severe congenital or acquired heart disease;


  • Conditions requiring long periods of intensive treatment aimed at prolonging quality of life such as human immunodeficiency virus (HIV), cystic fibrosis, severe gastrointestinal disorders or malformations such as gastroschisis, severe epidermolysis bullosa, severe immunodeficiencies, renal failure when dialysis and/or transplantation are not available or indicated, chronic or severe respiratory failure, or muscular dystrophy;


  • Progressive conditions in which treatment is exclusively palliative from diagnosis such as mucopolysaccharidoses or other storage disorders, progressive metabolic disorders, certain chromosomal abnormalities such as Trisomy 13 or Trisomy 18, or severe forms of osteogenesis imperfecta; and


  • Conditions with severe, non-progressive disability, causing extreme vulnerability to health complications such as severe cerebral palsy with recurrent infection or difficult symptoms, extreme prematurity, severe neurologic sequelae of infectious disease, hypoxic/anoxic brain injury, or holoprosencephaly or other severe brain malformations. Given the uncertainty of prognosis, many children with these conditions will not fit eligibility criteria for hospice care in the United States (6).


Epidemiology of Suffering

Despite best efforts, children living with chronic, life-threatening, and terminal illnesses experience substantial suffering. This experience of serious disease is multidimensional. It has broad-ranging implications in the child’s life as a whole and in the family as a functional unit. Suffering results from a threat to one’s physical and psychological self, from a threat to one’s relationships with others, and from a threat to one’s relationship with a transcendent source of meaning (7). Suffering is a profoundly personal experience and is endurable, and at times even fulfilling, when it becomes meaningful (8). Serious illness threatens children’s sense of personal integrity and shatters all aspects of their lives. Physical pain and other symptoms cause fear, depression, and isolation. Illness affects their daily activities, sense of well-being, physical strength and agility, and the motives and quality of their relationships. Disease crushes their sense of security, and brings fears of the unknown, rejection,
and punishment. Children also become confused by the experience of a mixed variety of emotions of anger, anxiety, sadness, loneliness, and isolation in the presence of a threatening situation (9). Children are highly vulnerable to the stress inherent to the experience of severe illness. They have an egocentric view of the world and lack a fully developed repertoire of coping mechanisms, such as problem solving or decision making, which are influenced by age-dependent behavior and cognitive abilities.

Within the physical realm, the published experience speaks best to those with malignant diseases. Recent studies by Wolfe (10) and Collins et al. (11, 12). point to the wide variety and high prevalence of symptoms from which children with life-threatening illness suffer. There appears to be significant discrepancies between the reports of parents and physicians regarding the children’s symptoms in the last month of life, with parents reporting each symptom more than the physicians. Furthermore, currently available treatments may not be successful in easing suffering associated with these symptoms that can cause significant distress. For children with nonmalignant diseases, some of the more troublesome symptoms might include gastroesophageal reflux, neuroirritability, immobility, incontinence, seizures, muscle spasms, pressure ulcers, contractures, recurrent infections, increased secretions, restlessness, sleep disturbance, and edema. There are few valid and reliable tools available to assess these symptoms and little data to substantiate the use of many of the interventions currently prescribed.

Suffering, for the parents of a child with a life-threatening illness, can also be a multidimensional experience of pain, fear, failure, despair, powerlessness, hopelessness, purposelessness, and vulnerability. Parental anxiety is due in part to the changing parent-child structure, the need to understand the illness experience, become familiar with the hospital environment, adapt to the changing relationships with their child and other family members, and negotiate with professionals about their care (13, 14). Parents must also deal not only with the immediate threat of disease on their child’s life, but also with important additional family stressors during treatment such as lifestyle changes, marital tension, financial strain, loss of self-esteem, and even loss of sleep (15). Furthermore, when confronted with the suffering and possible death of their child, parents frequently recognize their own limitations and mortality. Their perception of life, death, and the world around them is changed dramatically by the reality of the loss of their child. In addition, parents must also satisfy the emotional needs of other children in the family which many times parallel those of the seriously ill child (16). Finally, children and their families may also suffer spiritually. This may be manifested as a sense of isolation and abandonment, a sense of hopelessness and uncertainty about the meaning and ultimate purpose of life.

The American Academy of Pediatrics supports an integrated model of palliative care in which the components of palliative care are offered at diagnosis and continued throughout the course of illness, whether the outcome ends in cure or death (17). Basic principles of pediatric palliative care include the following:



  • Care is child-focused, family oriented and relationship-centered


  • Care focuses on relief of suffering and enhancing quality of life for the child and family


  • All children suffering from chronic, life-threatening and terminal illnesses are eligible


  • Care is provided for the child as a unique individual and the family as a functional unit


  • Palliative care is incorporated into the mainstream of medical care regardless of the curative intent of therapy


  • Care is not directed at shortening life


  • Care is coordinated across all sites of care delivery


  • Care is goal directed and is consistent with the beliefs and values of the child and his or her caregivers


  • An interdisciplinary team is always available to families to provide continuity


  • Advocacy for participation of the child and caregivers in decision making is paramount


  • Facilitation and documentation of communication are critical tasks of the team


  • Respite care and support are essential for families and caregivers


  • Bereavement care should be provided for as long as needed


  • “Do Not Resuscitate” orders should not be required and


  • Prognosis for short-term survival is not required

These essentials do not mandate a particular structure for care delivery other than to suggest the function of an interdisciplinary team of health care and allied health care professionals to provide care coordination and to facilitate the delivery of services with the goal to minimize suffering and improve quality of life.


Advanced Care Coordination

Much of the fragmentation of services that occurs in modern health care systems results from the lack of a coordinating entity. The loss of continuity may be addressed by providing a medical home for these children along with the services of an advanced-illness care coordinator. This may be a registered nurse whose primary responsibilities are to enhance communication across settings, facilitate the participation of the patient and family in the decision-making process, ensure that health care providers adhere to the goals and principles of palliative care, and honor the patient and family’s wishes. The coordinator may also be responsible for ensuring access to proper management of pain, and psychosocial and spiritual support. The advanced-illness care coordinator may advocate for change in the nature of the palliative care interventions according to the stage of disease and the patient and family’s expectations, values, and beliefs. In our experience, provision of a trained advanced-illness care coordinator to facilitate end-of-life communication also increases utilization of and length of stay in end-of-life services and completion of advance directives. The roles provided by a physician advocate and the integration of services facilitated by the advanced care coordinator are essential for maintaining a patient-focused, relationship-centered approach and promotion of palliative care goals (18).


Ethical Issues

Shared decision making in pediatrics, driven by communication between child, parent, and physician, defines the standard in medical ethics. Clinicians must establish an effective process to ensure that all treatment decisions are made in the best interest of the child. Understanding the illness experience from the perspective of the child and family, establishing accurate prognosis and communicating it effectively, setting reasonable goals and establishing a comprehensive advanced-illness care plan are indispensable steps in this process. Judgments that relate to withholding and/or withdrawing certain therapies, as well as judgments concerning medically inappropriate interventions, are essentially subjective but realistically indispensable (19). There is marked variability among physicians regarding the use of artificial life support, but in general, these decisions must be goal directed and in consonance with the child’s and family’s beliefs and values (20).


Withholding and withdrawing artificial life-sustaining interventions in children, particularly medically provided artificial hydration and nutrition, is often controversial. However, in patients with no hope of regaining some potentiality for function, clinicians may find insufficient justification for continued treatment if the burden of therapy is greater than the benefits to the patient and family (21, 22). Discontinuation of nonbeneficial interventions is squarely within the scope of parental decision-making authority for their child and is not inconsistent with the child’s best interests. Although children are allowed to assent rather than to consent to plans regarding their care, parents and health care providers must recognize the subjective personal nature of suffering and respect the child’s autonomy and capacity to make decisions, particularly for emancipated and mature minors (23). Whenever possible, caregivers must make an effort to invite children to participate in medical decision making and honor their end-of-life care wishes. This is particularly important for any child, regardless of age, who can understand his or her medical condition, who can communicate his or her preferences, and who is able to reach a reasonable decision and can understand its consequences (24). In addition, the principles that guide the rule of double effect and sedation of highly symptomatic patients with pain or dyspnea in adults also apply in the care of children (25). In difficult cases, institutional ethics committees can help resolve conflicts about treatment decisions, provide a forum for discussion of hospital policies, and educate the health care community about ethical concepts (26). Of note, although some alternative medicine practices in the care of seriously ill children may be justified; there are no published guidelines for the use of these practices in children (27). Parents of seriously ill children may be willing to try a variety of approaches, some of which may be potentially harmful, hoping for benefit in a desperate situation, particularly when the condition imposes a heavy burden for which mainstream therapies are insufficient (28). To best serve the interest of children, physicians must maintain a scientific perspective, provide balanced advice about therapeutic options, and establish and maintain a trusting relationship with families (29).


Symptom Control


Pain Assessment and Management

Pain is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (30). Several outstanding and more comprehensive resources are available for pain management in children (31, 32, 33, 34). It is subjective in nature. The experience of pain can be modulated by environmental, developmental, behavioral, psychological, familial, and cultural factors. Unrelieved pain for the child can produce fear, mistrust, irritability, impaired coping, and posttraumatic stress symptoms. Parents feel guilt and anger when pain is undertreated. Many children have pain at some time during their course with life-threatening illness; it can be disease related, treatment related, and/or related to psychological distress. Incidental, or traumatic pain, can still occur in a life-threatened child as well.

Pain assessment must be age-appropriate and requires a careful history and physical examination, determination of the primary cause(s) of pain, and evaluation of secondary causes and modulating features. Pain complaints should always be taken seriously; severe pain for a child is a medical emergency.

Elements of the pain assessment should include the quality of the pain, region and radiation, severity, temporal factors, and provocative and palliative factors. Additional historical elements include disease stage and context, fear of pain, ability to take medication, prior analgesic use, potential role of disease-specific treatment, reactions of parents and family context, and other nonpain symptoms, including depression and/or anxiety, sleep disturbance, and most important, interference with activities of daily life, including play.

Methods of pain assessment must be appropriate to the child’s age, situation, emotional resources, developmental level and context, and wishes of the child and family. Ideally, pain assessment, being subjective, should be by self-report. For children >7 years of age, visual analogue or verbal response scales are appropriate. For children ages 3–7, several validated, self-report tools are available, including Faces Scale (35), Oucher (36), poker chip tool (37), body maps, and pain thermometers (38). The Bieri modification of the Faces Scale has improved morphometrics and score distribution (39, 40).

For infants, toddlers, and preverbal children, several behavioral assessment scales exist, including CRIES (41), the Neonatal Infant Pain Scale (42), and Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS) (43) among others (44). Tools for the assessment of pain in the cognitively impaired child have also been described (45). In general, pain management for children should follow the World Health Organization analgesic ladder (46). Table 73.1 lists some of the more commonly used and available medications for mild, moderate, and severe pain. Particularly for children who cannot swallow pills, the long half-life, low cost, and availability in concentrated liquid formulation make methadone a good choice for long-term analgesia and for preventing opioid withdrawal symptoms (47, 48). A short initial and long terminal half-life requires judicious titration to prevent oversedation. Given toxic metabolite accumulation and the availability of several alternatives, meperidine cannot be recommended and is excluded from the table. Medications for pain should be administered according to a regular schedule. Rescue doses should be provided for intermittent or more severe breakthrough pain. Effective management of procedural pain is as critical as expert anticipation, prevention, and treatment of medication side effects. (49, 50). Depending on the etiology of the pain being treated, there are many nonopiate adjunct therapies available. Table 73.2 lists some of the more commonly used medications and their indications.








Table 73.1 Opioid and Nonopioid Analgesics
















































































































































Drug Initial dose (mg/kg/dose) Route Interval Maximum dose Formulation
Acetaminophen 10–15 p.o./p.r. q4h 1 g/dose; 4 g/d T, CT, L, D, S
Ibuprofen 5–10 p.o. q6h 2.4 g/d; 3.4 g/d (adults) T, CT, L, D
Choline magnesium trisalicylate 7.5–20 p.o. b.i.d.–t.i.d. 1.5 g/dose T, L
Naproxen 5–7 p.o. q8–12 h 1 g/d T, L
Ketorolac 0.5 p.o., i.v., i.m. q6h 30 mg/dose i.v., 10 mg/dose p.o. I, T
Codeine 0.5–1 p.o., s.q., i.m. q3–4 h 60 mg/dose T, L, I
Tramadol 1–2 p.o. q6h 100 mg/dose, 400 mg/d T
Morphine 0.2–0.5 p.o., s.l., p.r. q3–4 h Titrate T, L, D, S
  0.1 i.v., s.q., i.m. q2–4 h Titrate I
  0.3–0.6 (long-acting) p.o. q8–12 h Titrate SRT
Hydromorphone 0.03–0.08 p.o., p.r. q3–4 h Titrate T, L, S
  0.015 i.v., s.q., i.m. q2–4 h Titrate I
Methadone 0.2 p.o. q8–12 h Titrate T, L
  0.1 i.v., s.q., i.m. q8–12 h Titrate I
Fentanyl 0.5–1 μg/kg/h Transdermal q48–72 h Titrate P
  5–15 μg/kg (sedative) t.m. q4–6 h Titrate LO
  1–2 μg/kg i.v., s.q. q1–2 h Titrate I
Oxycodone 0.05–0.15 p.o. q6h Titrate T, L
  0.1–0.3 (long-acting) p.o. q12h Titrate SRT
CT, chewable tablet; D, drops; I, injection; L, liquid; LO, lozenge; P, patch; S, suppository; SRT, sustained release tablet; T, tablet or capsule.








Table 73.2 Adjuvant Drugs Useful in Pediatric Pain Management












































































































































































Drug Initial dose (mg/kg/dose) Route Interval Maximum dose Formulation Indication
Amitriptyline 0.1 p.o. q.h.s. 2 mg/kg/d T, I Neuropathic pain, depression, sleep disturbance
Nortriptyline 0.2–0.5 p.o. q.h.s. 3 mg/kg/d T, L Neuropathic pain, depression, sleep disturbance
Paroxetine 10 mg/dose p.o. q.a.m. 60 mg/d T, L, SRT Neuropathic pain, depression
Fluoxetine 0.2 p.o. q.a.m. 80 mg/d T, L, SRT, 90 mg/q/wk Neuropathic pain, depression
Carbamazepine 2.5–5 p.o., p.r. b.i.d.–q.i.d. 2400 mg/d T, L, SRT, CT Neuropathic pain
Valproic acid 5 p.o. q.d.–t.i.d. 60 mg/kg/d T, L, SRT Neuropathic pain
  5 i.v. q6–8 h   I  
  10–15 p.r. q8h   L  
Clonazepam 0.003–0.01 p.o. t.i.d.–q.i.d. 0.2 mg/kg/d T Neuropathic pain
Gabapentin 5 p.o. b.i.d.–t.i.d. 2400 mg/d T, L Neuropathic pain
Methylphenidate 0.1 p.o. q4h–q24 60 mg/d T, SRT Coanalgesia, decreased sedation with opiates
Dextroamphetamine 0.1 p.o. q4h–q24 40 mg/d T, SRT Co-analgesia, decreased sedation with opiates
Diazepam 0.1–0.2 i.v., i.m. q2–4 h 10 mg/dose T, L, I Anxiety, muscle spasm
  0.2–0.3 p.o. q4–6 h 10 mg/dose T, L  
  0.3–0.5 p.r. q2–4 h 20 mg/dose I, S  
Midazolam 0.05–0.1 i.v., s.q., i.m. q2–4 h 2.5 mg/dose I Anxiety, muscle spasm
  0.2–0.3 Intranasal     I  
  0.25–0.5 p.o.     L  
Lorazepam 0.05 p.o., s.l., p.r., i.v., i.m. q4–6 h 2 mg/dose T, L, I Anxiety, muscle spasm
Dexamethasone Varies by indication p.o., i.v., i.m., s.q. q6–12 h 10 mg/dose T, L, I Bone pain, increased intracranial pressure
CT, chewable tablet; I, injection; L, liquid; S, suppository; SRT, sustained release tablet or capsule; T, tablet or capsule.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Aug 24, 2016 | Posted by in ONCOLOGY | Comments Off on Palliative Care in Pediatrics

Full access? Get Clinical Tree

Get Clinical Tree app for offline access